A carregar...
The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms
The inflammation-mediated comorbidities in myelofibrosis (MF) and related neoplasms (MPNs) likely reflect the concurrent immune deregulation and systemic inflammatory nature of the MPNs, emphasizing the link between chronic systemic inflammation, immune deregulation, and the malignant clone. JAK1-2...
Na minha lista:
| Publicado no: | Clin Case Rep |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4498871/ https://ncbi.nlm.nih.gov/pubmed/26185657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.281 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|